doi:10.1093/jac/dkl356 Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic mode
Minimal inhibitory concentration-based pharmacokinetic/pharmacodynamic (PK/PD) indices are commonly ...
Antibiotic resistance is becoming an accelerating issue, both in the treatment of nosocomial infecti...
The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-l...
Objectives: To compare in an in vitro kinetic model the pharmacodynamics of moxifloxacin and levoflo...
AbstractThe aim of this work was to compare the pharmacological properties of levofloxacin and gatif...
Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacoki...
A model for in-vitro simultaneous simulation of two different patterns of pharmacokinetic parameters...
Although levofloxacin has been used for the last 25 years, there are limited pharmacokinetic data to...
The purpose of this study was to explore the population pharmacokinetic features of levofloxacin in ...
dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacody...
Objective: The purpose of this study was to explore the population pharmacokinetic features of moxif...
The increasing frequency of penicillin-resistant pneumococcus continues to be of concern throughout ...
AbstractObjectiveTo assess the antibacterial action of moxifloxacin on Haemophilus influenzae and Mo...
none6noObjective: To investigate the pharmacokinetics of levofloxacin and the pharmacokinetic-pharma...
Levofloxacin is in a class of antibiotics known as fluoroquinolones, which treat infections by killi...
Minimal inhibitory concentration-based pharmacokinetic/pharmacodynamic (PK/PD) indices are commonly ...
Antibiotic resistance is becoming an accelerating issue, both in the treatment of nosocomial infecti...
The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-l...
Objectives: To compare in an in vitro kinetic model the pharmacodynamics of moxifloxacin and levoflo...
AbstractThe aim of this work was to compare the pharmacological properties of levofloxacin and gatif...
Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacoki...
A model for in-vitro simultaneous simulation of two different patterns of pharmacokinetic parameters...
Although levofloxacin has been used for the last 25 years, there are limited pharmacokinetic data to...
The purpose of this study was to explore the population pharmacokinetic features of levofloxacin in ...
dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacody...
Objective: The purpose of this study was to explore the population pharmacokinetic features of moxif...
The increasing frequency of penicillin-resistant pneumococcus continues to be of concern throughout ...
AbstractObjectiveTo assess the antibacterial action of moxifloxacin on Haemophilus influenzae and Mo...
none6noObjective: To investigate the pharmacokinetics of levofloxacin and the pharmacokinetic-pharma...
Levofloxacin is in a class of antibiotics known as fluoroquinolones, which treat infections by killi...
Minimal inhibitory concentration-based pharmacokinetic/pharmacodynamic (PK/PD) indices are commonly ...
Antibiotic resistance is becoming an accelerating issue, both in the treatment of nosocomial infecti...
The fluoroquinolones have moderate to excellent bioavailability, moderate to long elimination half-l...
DOI
Add to ORKG